Tryptamine Therapeutics(AU:ENP)
A$0.030.00 (0.00%)
AU:ENP
Tryptamine Therapeutics ownership
A$0.03
At close:0.00 (0.00%)
Want to see AU:ENP full AI Analyst Report?
Tryptamine Therapeutics (ENP) Ownership - Who Owns Tryptamine Therapeutics?
19 Followers
Tryptamine Therapeutics (ENP) Ownership Overview
- 11.50% Insiders
- 88.50% Public Companies and Individual Investors
The ownership structure of Tryptamine Therapeutics (AU:ENP) stock is a mix of institutional, retail, and individual investors. , 11.50% is owned by Insiders, and 88.50% is owned by Public Companies and Individual Investors.
The ownership structure of Tryptamine Therapeutics (AU:ENP) stock is a mix of institutional, retail, and individual investors. , 11.50% is owned by Insiders, and 88.50% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 13, 2026 | Jason Alan Carroll | AU$45,604 | |
| Apr 19, 2026 | Chris Ntoumenopoulos | AU$100,000 | |
| Apr 19, 2026 | Daniel Tillett | AU$170,000 | |
| Apr 19, 2026 | Jason Alan Carroll | AU$150,000 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Daniel Tillett | 67,000,000 | Insider | 4.10% | 1,206,000 |
| Jason Alan Carroll | 62,500,000 | Insider | 3.82% | 1,125,000 |
| Herwig Janssen | 39,304,107 | Insider | 2.41% | 707,474 |
| Chris Ntoumenopoulos | 19,191,176 | Insider | 1.17% | 345,441 |
FAQ
What percentage of Tryptamine Therapeutics (AU:ENP) stock is held by retail investors?
According to the latest TipRanks data, approximately 88.50% of Tryptamine Therapeutics (AU:ENP) stock is held by public companies and individual investors.
Who owns the most shares of Tryptamine Therapeutics (AU:ENP)?
Daniel Tillett owns the most shares of Tryptamine Therapeutics (AU:ENP).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

